SYLENTIS
Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action. The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and ce... ntral nervous system diseases. Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company
SYLENTIS
Industry:
Biotechnology
Founded:
2006-01-01
Address:
Madrid, Madrid, Spain
Country:
Spain
Website Url:
http://www.sylentis.com
Total Employee:
11+
Status:
Active
Contact:
34 91 804 7667
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving Google Tag Manager Euro Apple Mobile Web Clips Icon Google Font API Google Analytics Google Maps Content Delivery Network
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Neumedicines
Neumedicines is a biotechnology company that focuses on the development of protein therapeutics.
Xenova
Xenova publicly quoted biotechnology company focused on the development of novel drugs to treat cancer and addiction.
Current Employees Featured
Founder
Official Site Inspections
http://www.sylentis.com Semrush global rank: 8.56 M Semrush visits lastest month: 624
- Host name: ns621.webempresa.eu
- IP address: 178.33.161.178
- Location: Madrid Spain
- Latitude: 40.4143
- Longitude: -3.7016
- Timezone: Europe/Madrid
- Postal: 28008
More informations about "SYLENTIS"
About Sylentis – Sylentis
Sylentis holds a Certificate of Compliance with Good Manufacturing Practices from the Spanish Agency for Medicines and Health Products. Parque Tecnológico de Madrid (PTM) C/ Santiago Grisolía nº 2. 28760 - Tres Cantos, Madrid, …See details»
SYLENTIS - Crunchbase Company Profile & Funding
Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or …See details»
SYLENTIS - The Org
Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is …See details»
Sylentis Company Profile | Management and Employees List
Sylentis Profile and History Sylentis is a PharmaMar Group pharmaceutical company focused on the discovery and development of innovative therapies based on gene silencing technologies …See details»
SYLENTIS Financial Overview, Employee Count, and Competitors
Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is …See details»
Sylentis Company Profile - Office Locations, Competitors ... - Craft
Sylentis is a biotechnology company focused on the development of ophthalmic drugs and therapies based on RNAi (gene silencing) technology. It serves patients with dry eye, retina …See details»
Sylentis - VentureRadar
Similar Companies: Silence Therapeutics United Kingdom Publicly Traded Silence Therapeutics is developing a new generation of medicines by harnessing the body’s naturalmechanism of …See details»
Sylentis - Company Profile - Tracxn
Dec 7, 2024 Sylentis - Developer of siRNA-based formulations for the treatment of eye diseases. Raised funding over 1 round from 1 investor. Founded by Jose María Fernandez Sousa Faro …See details»
SYLENTIS SAU Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SYLENTIS SAU of MADRID, Madrid. Get the latest business insights from Dun & Bradstreet.See details»
Sylentis | AseBio - Asociación Empresas Biotecnología
Furthermore, Sylentis is focusing on post-traumatic neuron lesions and ischaemia, neurodegenerative diseases and dementia. Areas of interest for future collaborations Because …See details»
Sylentis - Overview, News & Similar companies | ZoomInfo.com
Who is Sylentis. Sylentis is a PharmaMar Group pharmaceutical company focused on the discovery and development of innovative therapies based on gene silencing techn ologies or …See details»
Corporate News – Sylentis
Sylentis, a wholly owned subsidiary of PharmaMar (MSE:PHM), has appointed Andreas Segerros as Chief Executive Officer (CEO). This new appointment aims to redirect Sylentis’ strategic …See details»
Sylentis SA - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Explore Sylentis SA with its drug pipeline, therapeutic area, technology platform, 15 clinical trials, 9 news, Disease Domain:Immune System Diseases, Technology …See details»
SYLENTIS - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Nov 10, 2024 Organization. SYLENTIS . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 49. Monthly …See details»
SYLENTIS - Contacts, Employees, Board Members, Advisors & Alumni
Organization. SYLENTIS . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. SYLENTIS has 2 current …See details»
Clinical trials - Sylentis
You can consult the clinical trials of which Sylentis is a sponsor HERE. Parque Tecnológico de Madrid (PTM) C/ Santiago Grisolía nº 2. 28760 - Tres Cantos, Madrid, Spain +34 91 804 76 67 …See details»
Media - Sylentis
Sylentis sponsors the 11th Annual meeting of the Oligonucleotide Therapeutics Society (OTS). The meeting will be held in Leiden (The Netherlands) 11-14th October, 2015. Oligonucleotide …See details»
Finalized projects - Sylentis
Public Organization: Title: H2020-NMP-2014-646142: 2018: Comisión Europea: A Pilot Plant for the Production of Polymer based Nanopharmaceuticals in Compliance with GMP. H2020-2014 …See details»
Pipeline - Sylentis
At Sylentis we are committed to health care and that is why we research and develop compounds that improve patients’ lives. We are currently developing a pipeline of products for the …See details»